Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge

Novo’s SELECT Readout For Wegovy May Answer Payer Questions

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.

healthy nutritional food eating lifestyle to prevent heart disease and diabetes
Showing that obesity drugs can improve diabetes and heart health may be key to reimbursement • Source: Shutterstock

While the GLP-1 agonists have been hailed for their double-digit percentage weight reductions in clinical trials presented at the recent American Diabetes Association (ADA) annual meeting, data on how significant weight loss can improve or prevent cardiometabolic comorbidities may be what is needed to improve payer coverage. Given the numbers of people eligible for treatment and the costs of new medicines, there are growing concerns that many who could greatly benefit from obesity drugs will not be able to access them.

Accessibility already is a problem for Novo Nordisk A/S’s Wegovy (semaglutide), which the company has struggled to manufacture at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains